-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest forecast data of Minai.
com, the terminal sales scale of proprietary Chinese medicines in China's urban physical pharmacies in 2022E exceeded 110 billion yuan, down 0.
99%
year-on-year.
198 proprietary Chinese medicines sold more than 100 million yuan, of which 100 rose "against the trend" (35 increased by more than 10%); 55 are exclusive varieties (including exclusive dosage forms), with Ling, Yunnan Baiyao, Tongrentang and other enterprises "dominating the screen"
.
com, the terminal sales scale of proprietary Chinese medicines in China's urban physical pharmacies in 2022E exceeded 110 billion yuan, down 0.
99%
year-on-year.
198 proprietary Chinese medicines sold more than 100 million yuan, of which 100 rose "against the trend" (35 increased by more than 10%); 55 are exclusive varieties (including exclusive dosage forms), with Ling, Yunnan Baiyao, Tongrentang and other enterprises "dominating the screen"
.
The 100 proprietary Chinese medicines cover 11 major treatment categories, focusing on the treatment areas of respiratory diseases, cardiovascular and cerebrovascular diseases, digestive diseases, and urinary diseases, accounting for more than 10%.
Distribution of 100 large categories of proprietary Chinese medicine treatment
OTC products dominate in brick-and-mortar pharmacies
.
Among the 100 proprietary Chinese medicines, 62 are OTC products, including 25 Class A OTC products and 20 Class A OTC (double-span) products; There are 11 Class B OTC products and 6 Class B OTC (double-span) products
.
.
Among the 100 proprietary Chinese medicines, 62 are OTC products, including 25 Class A OTC products and 20 Class A OTC (double-span) products; There are 11 Class B OTC products and 6 Class B OTC (double-span) products
.
Over 35 billion market! 7 more than 1 billion proprietary Chinese medicines are eye-catching
From the sales point of view, the total sales scale of 100 proprietary Chinese medicines in the terminal of China's urban physical pharmacies in 2022E will exceed 35 billion yuan, of which 7 proprietary Chinese medicines will exceed 1 billion yuan, including Angong Niuhuang Pill, Huo Xiang Zhengqi Oral Liquid, Stomach Elimination Tablets, Kyoto Nianci Honey Refining Chuanbei Loquat Ointment, Lianhua Qingwen Capsules, Pian Zixi (lozenges) and Enteritis Ning tablets
.
.
"First aid miracle medicine" Angong Niuhuang Pill is the leader, and sales have increased year after year, and it is expected that sales will exceed 3.
8 billion yuan in 2022; Huo Xiang Zhengqi Oral Liquid is expected to exceed 1.
8 billion yuan in 2022, and the sales growth rate of this product in the past three years has reached double digits; The sales of two exclusive proprietary Chinese medicines, Pian Zixi (lozenge) and Enteritis Ning tablets, have increased year after year, and it is expected that they will join the "billion" army
for the first time in 2022.
8 billion yuan in 2022; Huo Xiang Zhengqi Oral Liquid is expected to exceed 1.
8 billion yuan in 2022, and the sales growth rate of this product in the past three years has reached double digits; The sales of two exclusive proprietary Chinese medicines, Pian Zixi (lozenge) and Enteritis Ning tablets, have increased year after year, and it is expected that they will join the "billion" army
for the first time in 2022.
Terminal sales of some proprietary medicines in physical pharmacies in Chinese cities in recent years (: 10,000 yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
Recently, "Shijiazhuang Lianhua Qingwen capsules sold out" once rushed to the hot search
.
Driven by the epidemic, the sales of Lianhua Qingwen capsules in China's urban physical pharmacy terminals increased from more than 600 million yuan in 2019 to more than 1.
5 billion yuan in 2020, a year-on-year increase of about 149%.
Sales declined in 2021, but sales growth is expected to exceed 15%
in 2022.
.
Driven by the epidemic, the sales of Lianhua Qingwen capsules in China's urban physical pharmacy terminals increased from more than 600 million yuan in 2019 to more than 1.
5 billion yuan in 2020, a year-on-year increase of about 149%.
Sales declined in 2021, but sales growth is expected to exceed 15%
in 2022.
Sales of Lianhua Qingwen capsules in China's urban physical pharmacy terminals in recent years (: 10,000 yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
Katazai, Tai Chi.
.
.
35 proprietary Chinese medicines soared by more than 10%
.
.
35 proprietary Chinese medicines soared by more than 10%
In terms of growth rate, 35 out of 100 proprietary Chinese medicines will have sales growth of more than 10%
in China's urban physical pharmacy terminals in 2022E.
in China's urban physical pharmacy terminals in 2022E.
In 2022E, China's urban physical pharmacies sold more than 100 million yuan of proprietary Chinese medicines with a growth rate of more than 10%.
Source: Minainet Comprehensive Database
Sophora granules, honeysuckle oral liquid, and Lianhua Qingwen granules will increase by more than 80%.
Huai'er granules are not suitable for surgery and chemotherapy for primary liver cancer, and it is expected that the sales of 2022E will exceed 200 million yuan, and it will win the first
time in the ranking of anti-tumor proprietary Chinese medicine products.
Huai'er granules are not suitable for surgery and chemotherapy for primary liver cancer, and it is expected that the sales of 2022E will exceed 200 million yuan, and it will win the first
time in the ranking of anti-tumor proprietary Chinese medicine products.
The sales growth rate of 12 proprietary Chinese medicines exceeded 10% for three consecutive years, including Huai'er granules, honeysuckle oral liquid, Tongguanteng oral liquid (anti-cancer ping oral liquid), Pian Zixi capsules, Ginkgo biloba extract tablets, Gui Spleen Pills, Blood Plug Tong Soft Capsules, Musk Chasing Wind Ointment, Red Medicine Patch, Ginseng Jian Spleen and Stomach Granules, Huo Xiang Zhengqi Oral Liquid and Tin Maple Dou Granules
.
.
In recent years, the terminal sales of some proprietary medicines in physical pharmacies in Chinese cities have increased
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
Honeysuckle oral liquid and Clearance Oral Liquid (anti-cancer flat oral liquid) have increased by more than 50% in the past three years, and it is expected that the sales of 2022E will exceed 100 million yuan
for the first time.
Among them, honeysuckle oral liquid is the exclusive variety of Zhenao Honeysuckle Pharmaceutical, which has the effect of clearing heat and detoxification, evacuating wind heat, and can be used for heat stroke, prickly rash, boils, wind fever and colds caused by summer heat and internal crimes
.
for the first time.
Among them, honeysuckle oral liquid is the exclusive variety of Zhenao Honeysuckle Pharmaceutical, which has the effect of clearing heat and detoxification, evacuating wind heat, and can be used for heat stroke, prickly rash, boils, wind fever and colds caused by summer heat and internal crimes
.
With Lingba screen, 55 exclusive proprietary Chinese medicines rose against the trend
From the perspective of the number of manufacturers, 55 of the 100 proprietary Chinese medicines are exclusive varieties (including exclusive dosage forms).
Yiling Pharmaceutical, Beijing Tongrentang, Yunnan Baiyao, China Resources Pharmaceutical, Jichuan Pharmaceutical, Ma Yinglong Pharmaceutical, Sanjin Pharmaceutical, Taiji Group, Tasly, Zhangzhou Pian Zixi Pharmaceutical have 2 or more varieties listed.
Enterprises with 2 or more varieties among the 55 exclusive proprietary Chinese medicines
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
Yiling Pharmaceutical focuses on two therapeutic areas
: cardiovascular and cerebrovascular disease medication and respiratory disease medication with 5 varieties.
In the 2022E TOP10 manufacturers of terminal respiratory system patent medicine and cardiovascular and cerebrovascular proprietary Chinese medicine manufacturers in China's urban physical pharmacies, Yiling Pharmaceutical is on the list
.
From the perspective of sales growth, it is expected that Lianhua Qingwen capsules, Lianhua Qingwen granules, ginsengsong Yangxin capsules, and Qianqiangxin capsules will all exceed 10%.
: cardiovascular and cerebrovascular disease medication and respiratory disease medication with 5 varieties.
In the 2022E TOP10 manufacturers of terminal respiratory system patent medicine and cardiovascular and cerebrovascular proprietary Chinese medicine manufacturers in China's urban physical pharmacies, Yiling Pharmaceutical is on the list
.
From the perspective of sales growth, it is expected that Lianhua Qingwen capsules, Lianhua Qingwen granules, ginsengsong Yangxin capsules, and Qianqiangxin capsules will all exceed 10%.
Yunnan Baiyao series products (aerosols, plasters, powders, etc.
) are the core products of Yunnan Baiyao, and it is expected that the total sales scale of 2022E in China's urban physical pharmacy terminals will exceed 1.
6 billion yuan
.
In the ranking of patent drug manufacturers in the musculoskeletal system, Yunnan Baiyao has been among the best
for many years.
) are the core products of Yunnan Baiyao, and it is expected that the total sales scale of 2022E in China's urban physical pharmacy terminals will exceed 1.
6 billion yuan
.
In the ranking of patent drug manufacturers in the musculoskeletal system, Yunnan Baiyao has been among the best
for many years.
The series of products (lozenges and capsules) are the leading products of Zhangzhou Pian Zixi Pharmaceutical, and it is expected that the total sales scale of physical pharmacy terminals in Chinese cities in 2022E will exceed 1.
2 billion yuan, of which the sales growth rate of Pian Zixi capsules will exceed 50%.
2 billion yuan, of which the sales growth rate of Pian Zixi capsules will exceed 50%.
Taiji Group's acute bronchi syrup and sinusitis oral liquid are both Class A OTC (double-span) and medical insurance Class B varieties, and the sales growth rate of China's urban physical pharmacy terminals in 2022E will exceed 35%, of which the sales of sinusitis oral liquid will exceed 100 million yuan
for the first time.
for the first time.
Source: Minainet database and other Note: Minai.
com "China's Urban Physical Pharmacy Drug Terminal Competition Pattern", the statistical scope is: national prefecture-level and above urban physical pharmacies, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
com "China's Urban Physical Pharmacy Drug Terminal Competition Pattern", the statistical scope is: national prefecture-level and above urban physical pharmacies, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
